Abstract:Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score >= 9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score >= 14) received escitalopram (10-20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Asberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS <= 6) and 61.7% of patients achieved depression remission (MADRS <= 10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS <= 6 and MADRS <= 10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient's baseline SDS score was related with depression score (regression coeflicient=0.40582, y=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported r 1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10-20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified.

Clinical effects of escitalopram in the treatment of senile depression

A control study of Escitalopram and Venlafaxine in senile depression

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

To Observe the Therapeutic Effect of Escitalopram and Paroxetine on the Senile Depression

Efficacy and safety of escitalopram in treatment of depressive disorder

Clinical Research on Escitalopram Oxalate Tablets in Treatment of Depression

Escitalopram and sertraline in treatment of depression with anxiety

Efficacy and Safety of Escitalopram in Treatment of Severe Depression in Chinese Population.

A controlled study in the treatment of depression with escitalopram and paroxetine

Escitalopram Vs Citalopram: a Parallel Controlled Study for Depression

Effectiveness and Safety of Escitalopram and Duloxetine in the Treatment of Depression:a Meta-analysis

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

Comparison of Escitalopram with Citalopram in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Efficacy of Escitalopram in the treatment of major depressive disorders with anxiety symptoms

Clinical Efficacy of Vortioxetine in Treatment of Depressive Disorder

Escitalopram vs citalopram in treatment of depression:a randomized,double-blind,double-dummy,multicenter,parallel controlled study

Escitalopram Vs Citalopram for Depression:A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Controlled Study

COMPARATIVE STUDY OF DRUGS IN TREATMENT OF SENILE DEPRESSION